KIRKLAND, QC, Sept. 15, 2015 /CNW Telbec/ - ANRis Pharma Inc., a private Canadian biotech company focused on the development of a proprietary drug delivery technology, announced today the appointment of Dr. Joseph Elliot as President and CEO.
"As an early stage company focused on drug delivery, ANRis requires strong leadership with experience raising money and taking start ups through the difficult preclinical testing phase to successful exit," said Steve Saviuk, Chairman of ANRis Pharma. "Dr. Joe Elliot has the background and experience we need to position the company as a leader in the delivery of nucleic acid-based drugs. We are excited to have him join the organization."
" I am thrilled to be joining ANRis at this important time." said Dr. Elliot. "Nucleic acid drugs are a most promising new class of drugs to emerge in recent years and ANRis' delivery technology will play a major role in their success." Dr. Elliot will join the organization immediately and focus on securing funding to advance the preclinical program. In addition, he will identify partners seeking better delivery technologies for their own drug candidates and work with the ANRis research team to select targets for advancement of internal development programs.
Joseph Elliot is an experienced biopharmaceutical executive with a track record of leading start ups through to successful exits. Trained as a cell biologist, Dr. Elliot has worked with venture capital companies, investing in many early stage companies. As President and CEO of several start-up biotech companies, he has led these organizations through critical preclincial and clinical trials, developed and executed partnering strategies, and successfully negotiated exits through acquisitions.
About ANRis Pharma
ANRis Pharma Inc. is a Canadian biotech company dedicated to the development of a novel and proprietary technology capable of efficiently delivering nucleic acid drugs such as siRNA, mRNA, and DNA. The system has demonstrated the ability to target specific organs including kidney and liver. ANRis Pharma will concentrate internal development on drug targets in kidney disease. Based on a natural biopolymner, ANRis' delivery system can be adapted to deliver drugs to a wide range of targets and be used to treat disease by both up regulating and down regulating genes as required.
SOURCE ANRis Pharma Inc.
For further information: Company Contact: Joseph Elliot, PhD, President and CEO, email@example.com